/

Batteries & E-Mobility

/

ImmunityBio, Inc.

ImmunityBio, Inc.

ImmunityBio, Inc.

Verified Nov 2026

Batteries & E-Mobility

·

United States flag

San Diego, California

·

Since 2014

ImmunityBio, Inc. is a clinical-stage biotechnology company founded in 2014 and headquartered in San Diego, California. With 500–1,000 employees and an estimated revenue band of $100–250 million, the company develops next-generation immunotherapies targeting cancer and infectious diseases. Its lead product, ANKTIVA (N-803), an IL-15 superagonist, received FDA approval in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer and has expanded into lung cancer indications.

ImmunityBio, Inc.

Verified Nov 2026

AT A GLANCE

Founded

2014

Headquarters

United States flag

San Diego, California

Employees

500-1,000

Ownership

ImmunityBio, Inc. at a glance

Revenue

$100-250M

Est. band

Employees

500-1,000

Founded

2014

Headquarters

San Diego, California

Industries

Automotive

Electric Vehicles

Medical

Overview

ImmunityBio, Inc. is a clinical-stage biotechnology company founded in 2014 and headquartered in San Diego, California. With 500–1,000 employees and an estimated revenue band of $100–250 million, the company develops next-generation immunotherapies targeting cancer and infectious diseases. Its lead product, ANKTIVA (N-803), an IL-15 superagonist, received FDA approval in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer and has expanded into lung cancer indications.

At a glance

Attribute

Detail

Founded

2014

Headquarters

San Diego, California

Employees

500-1,000

Revenue

$100-250M (estimated)

Primary capability

Batteries & E-Mobility

What ImmunityBio, Inc. makes

The company's pipeline includes immunotherapy candidates targeting advanced solid tumors, colorectal cancer, glioblastoma, HIV, and HPV, with clinical trials conducted in collaboration with institutions such as the National Cancer Institute.

Latest developments

Facilities

ImmunityBio, Inc. is headquartered in San Diego, California. Public sources also reference these locations:

Company details

ImmunityBio reported net product revenue of $48.7 million in Q3 2026, representing 53 percent year-over-year growth, and operates as a subsidiary of NantWorks LLC. ImmunityBio, Inc. was founded in 2014, has an estimated 500-1,000 employees, and is headquartered in San Diego, California.

Frequently asked questions

What does ImmunityBio, Inc. make?

ImmunityBio, Inc. is a clinical-stage biotechnology company founded in 2014 and headquartered in San Diego, California. With 500–1,000 employees and an estimated revenue band of $100–250 million, the company develops next-generation immunotherapies targeting cancer and infectious diseases. Its lead product, ANKTIVA (N-803), an IL-15 superagonist, received FDA approval in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer and has expanded into lung cancer indications.

Where is ImmunityBio, Inc. headquartered?

ImmunityBio, Inc. is headquartered in San Diego, California (3530 John Hopkins Ct, San Diego, California, 92121-1121).

When was ImmunityBio, Inc. founded?

ImmunityBio, Inc. was founded in 2014.

How big is ImmunityBio, Inc.?

ImmunityBio, Inc. has an estimated 500-1,000 employees, with revenue in the $100-250M range (estimated).

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

San Diego, California (HQ)Headquarters · United States
San Diego, California (HQ)3530 John Hopkins Ct, San Diego, California, 92121-1121, United StatesHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.